The burden of chronic urticaria.

In one study, compared with other skin conditions, chronic urticaria was reported to have the second highest impact on quality of life, even higher than psoriasis.1

The impact of chronic urticaria on daily life is often underestimated.2,3 Chronic urticaria can have a substantial effect on a patient’s physical, emotional, social and economic well-being.


Patients who experience problems with4,5:

Graphic depicting the number of patients who experience pain and discomfort (63%), anxiety and depression (47%), sleep problems (56%) and difficulties carrying out usual activities (34%)


Common and debilitating effects of angioedema6–8:

Graphic highlighting the impact of angioedema in two out of three chronic spontaneous urticaria patients


The healthcare burden of chronic urticaria

The long wait experienced by many patients before diagnosis and/or appropriate referral also contributes to the healthcare burden of chronic urticaria.4,6

  • Mean diagnostic delay: 4 years6‡
  • Average trips to GP before diagnosis: 136‡
  • Patients presenting as an emergency at least once: 49%6‡


*Self-reported data from 673 patients with CSU in Canada, France, Germany, Italy, Spain, Netherlands and UK whose symptoms persisted for ≥12 months despite treatment.4
Self-reported data from 769 patients with chronic urticaria (hives lasting for >6 weeks) in France, Germany, Italy, Spain and UK.5
75 patients with CSU.6

CSU, chronic spontaneous urticaria; GP, general practitioner.


  1. Zuberbier T et al. Expert Rev Clin Immunol 2015;11(2):171–180.
  2. Kang MJ et al. Ann Dermatol 2009;21(3):226–229.
  3. Silvares MR et al. Rev Assoc Med Bras (1992) 2011;57(5):577–582.
  4. Maurer M et al. Allergy 2017;72(12):2005–2020.
  5. Balp MM et al. J Eur Acad Dermatol Venereol 2018;32(2):282–290.
  6. Mistry A. Chronic Spontaneous Urticaria: impact of the diagnostic delay on healthcare resources. The British Society for Allergy & Clinical Immunology (BSACI) annual meeting. Telford International Centre, UK. September 2015.
  7. Ferrer M et al. Eur J Dermatol 2017;27(5):455–463.
  8. Staubach P et al. Allergy 2018; 73(3):576–584.
Rate this content: 
No votes yet
XSU20-C014 July 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]